Posted On: 01/02/2015 7:36:18 PM
Post# of 30066
Jason Napodano's responses over the last few days.
********************************************************************************
WCoastGuynCA @WCoastGuynCA 8h8 hours ago
@JNapodano $AMBS -1:100 reverse split to up-list appears more likely than ever. Any chance Zacks raises it's rating above "Hold" afterwards?
GChurbzzz @Churbz83 8h8 hours ago
@WCoastGuynCA @JNapodano @G_Commish said no way at these
WCoastGuynCA @WCoastGuynCA 7h7 hours ago
@Churbz83 @JNapodano @G_Commish I have to agree that with the share price so low that it's unlikely Zacks would raise its rating.
Jason Napodano, CFA @JNapodano 7h7 hours ago
@wcoastguynca @churbz83 @g_commish My rating is 'Buy'. That's the highest Zacks rating. There is no more positive I can be on $AMBS
********************************************************************************
Jason Napodano, CFA @JNapodano · Dec 30
@piyushpreeti If you are asking if I think LymPro has utility, then yes - absolutely. But still al to of questions before we can model sales
Jason Napodano, CFA @JNapodano · Dec 30
@piyushpreeti We are still waiting to see the final data, the final version(s) and who will be selling it, so VERY difficult to predict now.
********************************************************************************
Dave @yayankee Dec 30
@JNapodano AMBS to discuss LP-002 at Biotech Showcase 1/14/15...any idea if the results announced will be a positive?
Jason Napodano, CFA @JNapodano Dec 30
@yayankee It's not a "positive" or "negative" thing. LymPro is a diagnostic, so they key questions will be on sensitivity & specificity.
********************************************************************************
RJ @RJ_Wing Dec 30
@JNapodano What are your thoughts on them releasing the data at the investor conference instead of now, due to "current dynamics"?
Jason Napodano, CFA @JNapodano Dec 30
@rj_wing I think he wants the opportunity to explain the data to the public, instead of just putting out the PR and twitter bombard him.
********************************************************************************
Piyush Pamecha @piyushpreeti Dec 30
@JNapodano @RJ_Wing Do you think companies would use #lympro ? or just continue with the conventional way of recruiting subjects...
Jason Napodano, CFA @JNapodano Dec 30
@piyushpreeti @RJ_Wing That's the $200 million question, isn't it?
********************************************************************************
Piyush Pamecha @piyushpreeti Dec 30
@JNapodano @RJ_Wing Do you think companies would use #lympro ? or just continue with the conventional way of recruiting suredts...
Jason Napodano, CFA @JNapodano Dec 30
@piyushpreeti If you are asking if I think LymPro has utility, then yes - absolutely. But still al to of questions before we can model sales
********************************************************************************
WCoastGuynCA @WCoastGuynCA 8h8 hours ago
@JNapodano $AMBS -1:100 reverse split to up-list appears more likely than ever. Any chance Zacks raises it's rating above "Hold" afterwards?
GChurbzzz @Churbz83 8h8 hours ago
@WCoastGuynCA @JNapodano @G_Commish said no way at these
WCoastGuynCA @WCoastGuynCA 7h7 hours ago
@Churbz83 @JNapodano @G_Commish I have to agree that with the share price so low that it's unlikely Zacks would raise its rating.
Jason Napodano, CFA @JNapodano 7h7 hours ago
@wcoastguynca @churbz83 @g_commish My rating is 'Buy'. That's the highest Zacks rating. There is no more positive I can be on $AMBS
********************************************************************************
Jason Napodano, CFA @JNapodano · Dec 30
@piyushpreeti If you are asking if I think LymPro has utility, then yes - absolutely. But still al to of questions before we can model sales
Jason Napodano, CFA @JNapodano · Dec 30
@piyushpreeti We are still waiting to see the final data, the final version(s) and who will be selling it, so VERY difficult to predict now.
********************************************************************************
Dave @yayankee Dec 30
@JNapodano AMBS to discuss LP-002 at Biotech Showcase 1/14/15...any idea if the results announced will be a positive?
Jason Napodano, CFA @JNapodano Dec 30
@yayankee It's not a "positive" or "negative" thing. LymPro is a diagnostic, so they key questions will be on sensitivity & specificity.
********************************************************************************
RJ @RJ_Wing Dec 30
@JNapodano What are your thoughts on them releasing the data at the investor conference instead of now, due to "current dynamics"?
Jason Napodano, CFA @JNapodano Dec 30
@rj_wing I think he wants the opportunity to explain the data to the public, instead of just putting out the PR and twitter bombard him.
********************************************************************************
Piyush Pamecha @piyushpreeti Dec 30
@JNapodano @RJ_Wing Do you think companies would use #lympro ? or just continue with the conventional way of recruiting subjects...
Jason Napodano, CFA @JNapodano Dec 30
@piyushpreeti @RJ_Wing That's the $200 million question, isn't it?
********************************************************************************
Piyush Pamecha @piyushpreeti Dec 30
@JNapodano @RJ_Wing Do you think companies would use #lympro ? or just continue with the conventional way of recruiting suredts...
Jason Napodano, CFA @JNapodano Dec 30
@piyushpreeti If you are asking if I think LymPro has utility, then yes - absolutely. But still al to of questions before we can model sales
(0)
(0)
